 BOSTON, Sept. 09, 2021 GLOBE NEWSWIRE -- Yumanity Therapeutics Nasdaq: YMTX, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanitys common stock. The option will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employees new hire date and the remainder vesting in equal monthly installments over the following three years. The option has an exercise price of 10.88 per share, which is equal to the closing price of Yumanitys common stock on September 1, 2021, the grant date for the stock option, has a ten-year term and is subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and a stock option agreement covering the grant. The stock option was granted as an inducement material to the employee entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635c4. 